HPRA Drug Safety Newsletter Edition 74

Download: hpra-drug-safety-newsletter-edition-74.pdf 255 KB

 The latest edition of the HPRA Drug Safety Newsletter (DSN) includes important updates to support the safe and appropriate use of the following medicines:

High-Strength Insulin Preparations.
Antiretroviral medicines-updated advice on lipodystrophy and lactic acidosis.
Natalizumab (Tysabri) - Updates to progressive multifocal leukoencephalopathy (PML) risk minimisation measures.
Fingolimod (Gilenya) - Risks related to its immunosuppressive effects.

« Back